The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

If you’re taking a GLP-1 medication, such as semaglutide (Ozempic or Wegovy), exercise is an essential part of your routine — and not just for weight loss reasons. “Exercise helps you maintain muscle ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a ...

Global Partners LP (NYSE: GLP) has just announced a quarterly cash distribution of $0.59375 per unit ($2.375 per unit on an ...

Researchers developing benchmarks for a blood-based test like those for measuring blood glucose and cholesterol ...

Eli Lilly has also signed deals with Ro, Form Health and 9am Health ... to third-party telehealth companies that can prescribe its GLP-1 weight loss and diabetes medications Mounjaro and Zepbound.

Diabetes, weight-loss meds ‘out of reach’ for many, I-MAK says Firms defend actions; Lilly calls report ‘grossly inaccurate’ Novo Nordisk A/S and Eli Lilly & Co. are using dense clusters of patents to ...

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, the non­prof­it drug pric­ing watch­dog, re­leased a new re­port on Wednes­day out­lin­ing po­ten­tial fed­er­al pol­i ...

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...